Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Brain Imaging01:14

Brain Imaging

Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incomplete Cognitive Assessment in Post-Acute Stroke Rehabilitation: Recovering Clinically Interpretable Relationships from Routine Neuropsychological Data.

NeuroRehabilitation·2026
Same author

Molecular and environmental drivers of tau post-translational modifications and tau pathology.

Ageing research reviews·2026
Same author

CD8⁺ T cells induce interstrand crosslinking-associated DNA damage in neurons.

bioRxiv : the preprint server for biology·2026
Same author

Efficient tag-less purification of recombinant human tau proteins.

Analytical biochemistry·2026
Same author

RNA-seq variants reveal distinct patterns in the aging epitranscriptome: an in-depth analysis of age-matched Alzheimer's Disease patients and a cognitively normal cohort.

bioRxiv : the preprint server for biology·2026
Same author

Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635.

Clinical and translational science·2026

Related Experiment Video

Updated: May 28, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Research towards tau imaging.

Jordan R Jensen1, Katryna Cisek, Kristen E Funk

  • 1Department of Molecular and Cellular Biochemistry, The Ohio State University College of Medicine, Columbus, OH, USA.

Journal of Alzheimer'S Disease : JAD
|October 6, 2011
PubMed
Summary
This summary is machine-generated.

Developing brain imaging agents for Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) requires high selectivity for tau lesions over amyloid-beta plaques. Recent preclinical advances aim to overcome this major barrier for accurate diagnosis and staging.

More Related Videos

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
09:12

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Published on: December 20, 2019

Related Experiment Videos

Last Updated: May 28, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
09:12

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Published on: December 20, 2019

Area of Science:

  • Neuroscience
  • Biomarker Development
  • Medical Imaging

Background:

  • Tau-bearing neurofibrillary lesions are key biomarkers for Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD).
  • Whole brain imaging methods offer potential for premortem diagnosis and staging of these neurodegenerative diseases.
  • Existing tau-binding compounds lack sufficient selectivity over amyloid-beta plaques.

Purpose of the Study:

  • To discuss the challenges in developing selective tau imaging agents.
  • To highlight recent preclinical advances in achieving tau lesion selectivity.
  • To address the need for improved diagnostic tools for tauopathies.

Main Methods:

  • Review of challenges in developing brain-penetrating compounds.
  • Discussion of preclinical strategies for enhancing tau aggregate binding selectivity.
  • Analysis of methods to differentiate tau lesions from amyloid-beta plaques.

Main Results:

  • The primary challenge is achieving high selectivity for tau lesions over other protein aggregates like amyloid-beta.
  • Preclinical research is making progress in developing imaging agents with improved tau binding specificity.
  • Overcoming off-target binding is crucial for accurate imaging of neurodegenerative diseases.

Conclusions:

  • Selective tau imaging agents are critical for accurate premortem diagnosis and staging of AD and FTLD.
  • Continued preclinical development is essential to overcome selectivity barriers.
  • Advances in this area promise improved diagnostic capabilities for tauopathies.